Elanco Releases 2024 Impact Report and Introduces New Framework
Elanco Animal Health (NYSE:ELAN) has released its 2024 Impact Report, introducing a new framework focused on four key communities: animals, customers, society, and employees. The company achieved significant milestones including $461 million in innovation revenue from new products like Zenrelia and Credelio Quattro, exceeding their target of $420-450 million.
Key achievements include becoming the #1 retail parasiticide dispenser in the U.S., launching Bovaer® for methane reduction in dairy cattle, and enrolling 11% of U.S. dairy herds in their UpLook sustainability database. The company demonstrated strong social impact through $400,000 in product donations, 26,000 volunteer hours, and improved employee engagement scores of 71% in Q1 2025.
Elanco Animal Health (NYSE:ELAN) ha pubblicato il suo Rapporto d'Impatto 2024, presentando un nuovo quadro focalizzato su quattro comunità chiave: animali, clienti, società e dipendenti. L'azienda ha raggiunto importanti traguardi, tra cui 461 milioni di dollari di ricavi da innovazione grazie a nuovi prodotti come Zenrelia e Credelio Quattro, superando l'obiettivo di 420-450 milioni di dollari.
Tra i risultati principali figurano il diventare il distributore numero 1 di parasiticidi al dettaglio negli Stati Uniti, il lancio di Bovaer® per la riduzione del metano nel bestiame da latte e l'iscrizione del 11% delle mandrie da latte statunitensi nel loro database di sostenibilità UpLook. L'azienda ha dimostrato un forte impatto sociale con 400.000 dollari in donazioni di prodotti, 26.000 ore di volontariato e un miglioramento del punteggio di coinvolgimento dei dipendenti al 71% nel primo trimestre del 2025.
Elanco Animal Health (NYSE:ELAN) ha publicado su Informe de Impacto 2024, presentando un nuevo marco centrado en cuatro comunidades clave: animales, clientes, sociedad y empleados. La compañía alcanzó hitos importantes, incluyendo 461 millones de dólares en ingresos por innovación provenientes de nuevos productos como Zenrelia y Credelio Quattro, superando su meta de 420-450 millones de dólares.
Logros clave incluyen convertirse en el distribuidor minorista número 1 de parasiticidas en EE.UU., lanzar Bovaer® para la reducción de metano en ganado lechero e inscribir al 11% de los rebaños lecheros estadounidenses en su base de datos de sostenibilidad UpLook. La compañía demostró un fuerte impacto social con 400,000 dólares en donaciones de productos, 26,000 horas de voluntariado y una mejora en la puntuación de compromiso de empleados del 71% en el primer trimestre de 2025.
Elanco Animal Health (NYSE:ELAN)는 2024년 임팩트 리포트를 발표하며 동물, 고객, 사회, 직원 등 네 가지 핵심 커뮤니티에 중점을 둔 새로운 프레임워크를 소개했습니다. 회사는 Zenrelia와 Credelio Quattro와 같은 신제품을 통해 4억 6,100만 달러의 혁신 매출을 달성하며 목표였던 4억 2,000만~4억 5,000만 달러를 초과 달성했습니다.
주요 성과로는 미국 내 소매 기생충 구제제 1위 유통업체가 되었고, 낙농 가축의 메탄 배출 저감을 위한 Bovaer®를 출시했으며, 미국 낙농 가축의 11%를 UpLook 지속 가능성 데이터베이스에 등록했습니다. 또한 40만 달러 상당의 제품 기부, 26,000시간의 자원봉사 활동, 2025년 1분기 직원 참여도 점수 71% 향상 등 강력한 사회적 영향을 입증했습니다.
Elanco Animal Health (NYSE:ELAN) a publié son rapport d'impact 2024, présentant un nouveau cadre axé sur quatre communautés clés : les animaux, les clients, la société et les employés. L'entreprise a atteint des jalons importants, notamment 461 millions de dollars de revenus issus de l'innovation grâce à de nouveaux produits tels que Zenrelia et Credelio Quattro, dépassant ainsi son objectif de 420 à 450 millions de dollars.
Parmi les réalisations clés figurent la position de distributeur numéro 1 de parasiticides en vente au détail aux États-Unis, le lancement de Bovaer® pour la réduction du méthane chez les bovins laitiers, ainsi que l'inscription de 11 % des troupeaux laitiers américains dans leur base de données de durabilité UpLook. L'entreprise a démontré un fort impact social avec 400 000 dollars de dons de produits, 26 000 heures de bénévolat et une amélioration du taux d'engagement des employés à 71 % au premier trimestre 2025.
Elanco Animal Health (NYSE:ELAN) hat seinen Impact Report 2024 veröffentlicht und dabei einen neuen Rahmen vorgestellt, der sich auf vier zentrale Gemeinschaften konzentriert: Tiere, Kunden, Gesellschaft und Mitarbeiter. Das Unternehmen erzielte bedeutende Meilensteine, darunter 461 Millionen US-Dollar Innovationsumsatz mit neuen Produkten wie Zenrelia und Credelio Quattro und übertraf damit sein Ziel von 420-450 Millionen US-Dollar.
Zu den wichtigsten Erfolgen zählen die Position als Nr. 1 im Einzelhandel für Parasitizide in den USA, die Einführung von Bovaer® zur Methanreduktion bei Milchkühen und die Aufnahme von 11 % der US-Milchviehherden in ihre UpLook-Nachhaltigkeitsdatenbank. Das Unternehmen zeigte auch eine starke soziale Wirkung durch 400.000 US-Dollar an Produktspenden, 26.000 Freiwilligenstunden und verbesserte Mitarbeiterbindungswerte von 71 % im ersten Quartal 2025.
- Innovation revenue reached $461 million in 2024, exceeding target of $420-450 million
- Achieved #1 position in U.S. retail parasiticide dispensing
- Employee engagement increased 4% year-over-year to 71% in Q1 2025
- Successfully reduced workplace incidents with 37% decrease in DART
- Helped U.S. dairy farmers earn approximately $10 million from carbon credit reductions
- None.
In launching a new approach to impact reporting, Elanco reaffirms its dedication to delivering lasting positive change. The report outlines eight core ambitions that shape Elanco's business and aim to generate a meaningful impact within the communities we serve worldwide.
"Elanco is dedicated to delivering positive impact through the work we do every day, bringing innovative solutions to veterinarians, farmers, and pet owners," said Jeff Simmons, President & CEO of Elanco. "We're proud to announce a new framework that further embeds our purpose within our business operations, driving growth, accountability, and lasting positive change for society. We celebrate the progress made for these communities of impact and remain committed to advancing our objectives while delivering meaningful value to all our stakeholders."
Key Highlights include:
Go Beyond for Animals: Our strong portfolio, high-impact innovation, unique market approach, and dedication to making life better compels us to Go Beyond for Animals.
- Brought key innovations to market, such as Zenrelia, Credelio Quattro, and Pradalex, driving
$461 million $420 million $450 million - Increased pet owner access to parasite protection: Ranked as #1 retail parasiticide dispensing in the
U.S. while expanding global retail offerings with AdTab and theU.S. launch of Pet Protect, a new line of veterinary-formulated pet supplements under the Advantage family umbrella. - Donated more than
$400,000 - Served as an inaugural signatory to the
U.S. Animal Research Openness Agreement (USARO), reinforcing Elanco's commitment to transparency in the use of animals in research.
Go Beyond for Customers: Our promise to advocate, earn trust, and solve big challenges to create value inspires us to Go Beyond for Customers.
- Launched Bovaer®, a first-of-its-kind methane-reducing feed ingredient for lactating dairy cattle.
- Advanced livestock sustainability with FDA approval of three combination clearances for Experior use with MGA® in finishing heifers.
- Enrolled
11% of theU.S. dairy herd into Elanco's UpLook database, a digital insights engine that helps farmers measure and track sustainability goals; allowingU.S. dairy farmers to earn around$10 million - Committed
$310,000
Go Beyond for Society: Our commitment to improving the health of people through animals, delivering reliable products, and safeguarding the food system drives us to Go Beyond for Society.
- Educated nearly 150 global producers via the Elanco Food Safety Programme to tackle Salmonella outbreaks in poultry.
- Dedicated over 730 volunteer hours in food pantries, collaborating with meal-packing organizations to pack over 115,000 meals in 2024.
- Recovered over
$7 million - Engaged in strategic partnership with Medgene to leverage innovative vaccine technology, including the commercialization of a Highly Pathogenic Avian Influenza (HPAI) vaccine for dairy cattle, once approved.
Go Beyond for Our People: Our unique purpose-driven culture encourages ownership, growth, and wellbeing, motivating us to Go Beyond for Our People.
- Achieved a
71% Employee Engagement Score as of Q1 2025, noting a4% increase from the same period a year ago. - Recorded more than 26,000 volunteer hours in 2024, contributing
$870,000 - Introduced a global machine safety campaign for personal health, safety, and environment (HSE), resulting in a
37% decrease in Days Away, Restricted, or Transferred (DART). - Successfully improved energy efficiency at the Kiel facility with an innovative HVAC system, achieving
100% renewable green electricity and100% neutral natural gas, compensated by certification.
Elanco invites all stakeholders to explore the full 2024 Impact Report and looks forward to further advancing our purpose of Making Life Better for animals, customers, society, and our people in everything we do.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-releases-2024-impact-report-and-introduces-new-framework-302492454.html
SOURCE Elanco Animal Health
FAQ
What was Elanco's (ELAN) innovation revenue in 2024?
How much of the U.S. dairy herd is enrolled in Elanco's UpLook database?
What was Elanco's employee engagement score in Q1 2025?
How much did Elanco donate in product value and volunteer hours in 2024?
What new sustainability product did Elanco launch for dairy cattle in 2024?
